ReviewDiabetology & metabolic syndrome2026
Protein lactylation in metabolic dysfunction-associated steatotic liver disease: a mechanistic review.
Review in Diabetology & metabolic syndrome, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent chronic liver disorder with limited therapeutic options. While its pathogenesis is complex, the underlying molecular drivers remain incompletely understood. Recently, protein lactylation, a novel lactate-derived post-translational modification (PTM), has emerged as a key regulator linking metabolic reprogramming to cellular function. This review elucidates the pivotal roles of protein lactylation throughout the progression of MASLD, from simple steatosis to metabolic dysfunction-associated steatohepatitis (MASH) and hepatocellular carcinoma, establishing a conceptual framework centered on the “lactate-lactylation-gene expression” axis and examining its dysregulation across hepatocytes, hepatic stellate cells, and immune cells throughout MASLD. Furthermore, we discuss emerging therapeutic strategies targeting the axis, aiming to provide a theoretical foundation for the development of precision medicine for MASLD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.